Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
МГУ, Москва
Список исп. литературыСкрыть список 1. National Institute for Clinical Excellence. Schizophrenia: full national clinical guideline on core interventions in primary and secondary care (интернет-ресурс). URL: http://www.nice.org.uk/nicemedia/pdf/cg001fullguideline.pdf. Доступ 10.02.2009. 2. Kastrup MC, Baez-Ramos A. Globalmental health. Dan Med Bull 2007; 54 (1): 42–3. 3. Basar E, Guntekin B. A review of brain oscillations in cognitive disorders and the role of neurotransmitters. Brain Res 2008; 1235: 172–93. 4. Figueroa C, BrecherM, Hamer-Maansson JE et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psych 2009; 33 (17): 199–204. 5. Gunasekara NS, Spencer CM. Quetiapine: a review of its use in schizophrenia. CNS Drugs 1998; 9 (4): 325–40. 6. Cheer SM, Wagstaff AJ.Quetiapine: a review of its use in the management of schizophrenia. CNS Drugs 2004; 18 (3):173–99. 7. Keating GM, Robinson DM. Quetiapine: a review of its use in the treatment of bipolar depression. Drugs 2007; 67 (7): 1077–95. 8. Medicines Evaluation Board. Public assessment report of the medicines evaluation board in the Netherlands [интернет-ресурс]. URL: http://db.cbg-meb.nl/mri/par/nlh-0156-008-009-010-011.pdf. Доступ 10.02.2009. 9. AstraZeneca. Seroquel XR and Seroquel approved in Europe for new indications for the treatment of bipolar disorder (интернет-ресурс). URL: http://www.astrazeneca.com/media/latest-press-releases/5413?itemId=4179301. Доступ 19.03.2009. 10. US FDA. Prescribing information. Seroquel XR (quetiapine fumarate) extended-release tablets (интернет-ресурс).URL: http://www.fda.gov/cder/foi/label/2008/022047s006s007s008lbl.pdf. Доступ 10.02.2009. 11. Electronic Medicines Compendium. Seroquel XL 50 mg, 200 mg, 300 mg, 400 mg prolonged-release tablets: summary of product characteristics [интернет-ресурс]. URL: http://emc.medicines.org.uk/medicine/21175/SPC/Seroquel+XL+50+mg%2c+200+mg%2c+300+mg%2c+400+mg+prolonged-release+tablets/. Доступ 10.02.2009. 12. Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1А agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology 2008; 33: 2303–12. 13. Nyberg S, Takano A, Jucaite A et al. PET-measured occupancy of the norepinephrine transporter by extended release quetiapine fumarate in brains of healthy subjects (abstract no. NR5-126). 161st Annual Meeting of the American Psychiatric Association 2008 May; 3–8; Washington, DC. 14. Mamo DC, Uchida H, Vitcu I et al. Quetiapine extended release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry 2008; 69 (1): 81–6. 15. Juckel G, Winter HR, Stahle L et al. The pharmacokinetics of extended release quetiapine fumarate are not affected by a light meal (poster). 14-th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 2008 Feb: 3–7. 16. Peuskens J, Trivedi J, Malyarov S et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients (интернет-ресурс). URL: http://www.psychiatrymmc.com/category/archived-issues/11-2007-november-2007/. Доступ 23.02.2009. 17. Moller HJ, Johnson S, Mateva T et al. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int Clin Psychopharmacol 2008; 23 (2):95–105. 18. Kahn RS, Schulz SC, Palazov VD et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68 (6): 832–42. 19. Lindenmayer J, Brown D, Liu S, et al. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Psychopharmacol Bull 2008; 41 (3): 11–35. 20. Meulien D, Brecher M, Huizar K. Once-daily extended release quetiapine fumarate (quetiapine XR): pooled safety data from 3 placebo-controlled monotherapy studies in acute schizophrenia (abstract no. P0174). Eur Psych 2008; 23: 132. 21. AstraZeneca. A 6-week, multicenter, double-blind, double-dummy, randomized comparison of the efficacy and safety of sustained-release formulation quetiapine fumarate (SeroquelTM) and placebo in the treatment of acutely ill patients with schizophrenia (интернет-ресурс). URL: http://www.astrazenecaclinicaltrials.com/_mshost2715844/content/content/resources/media/2958892/d1444c00133.pdf. Доступ 10.02.2009. 22. Ganesan S, Agambaram V, Randeree F et al. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin 2008; 24 (1): 21–32.